<p>Assenagon Asset Management S.A. 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）股票中的持倉降低了 28.4%。該機構投資者在此期間出售了 26,119 股後，持有該公司 65,756 股股票。Assenagon Asset Management S.A. 在最近一個季度末持有 Protagonist Therapeutics 0.11% 的股份，價值 4,368,000 美元。</p>
<ul>
<li>強生的併購策略才是投資者真正關注的故事</li>
</ul>
<p>其他一些對沖基金和機構投資者最近也買賣了該公司的股票。Guggenheim Capital LLC 在第二季度將其在 Protagonist Therapeutics 的持倉增加了 1.6%。Guggenheim Capital LLC 目前持有該公司 19,208 股股票，價值 1,062,000 美元，此前在上個季度又增持了 303 股。Bessemer Group Inc. 在第二季度將其在 Protagonist Therapeutics 的股份提高了 171.0%。Bessemer Group Inc. 目前持有該公司 504 股股票，價值 28,000 美元，此前在上個季度又購買了 318 股。滙豐控股 PLC 在第一季度將其在 Protagonist Therapeutics 的股份提高了 4.1%。滙豐控股 PLC 目前持有該公司 8,458 股股票，價值 405,000 美元，此前在上個季度又增持了 330 股。未來資產全球投資有限公司在第二季度將其在 Protagonist Therapeutics 的持倉增加了 16.6%。未來資產全球投資有限公司目前持有該公司 2,394 股股票，價值 132,000 美元，此前在上個季度又購買了 340 股。最後，未來資產全球 ETF 持有有限公司在第一季度將其在 Protagonist Therapeutics 的股份增加了 0.9%。未來資產全球 ETF 持有有限公司目前持有該公司 37,403 股股票，價值 1,810,000 美元，此前在上個季度又增持了 348 股。目前，98.63% 的股票由機構投資者和對沖基金持有。</p>
<h2>Protagonist Therapeutics 的內部買賣</h2>
<p>在 Protagonist Therapeutics 的其他消息中，董事 William D. Waddill 於 10 月 10 日星期五出售了 12,000 股 Protagonist Therapeutics 股票。該股票以平均價格 81.62 美元出售，總價值為 979,440.00 美元。交易後，該董事直接持有該公司 5,130 股股票，價值約 418,710.60 美元。此交易代表其持倉減少了 70.05%。該出售在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。公司內部人士持有該公司 4.90% 的股票。</p>
<h2>Protagonist Therapeutics 股票表現</h2>
<ul>
<li>這隻小型生物科技股票是否還有（更多）大幅上漲的空間？</li>
</ul>
<p>NASDAQ PTGX 週一開盤價為 86.05 美元。該公司的 50 日移動平均線為 83.39 美元，200 日移動平均線為 66.53 美元。Protagonist Therapeutics, Inc. 的一年最低價為 33.70 美元，一年最高價為 96.54 美元。該公司的市值為 53.8 億美元，市盈率為 138.79，貝塔值為 2.19。</p>
<p>Protagonist Therapeutics（NASDAQ:PTGX - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告的每股收益（EPS）為（0.62）美元，低於分析師一致預期的（0.59）美元，差距為（0.03）美元。該公司本季度的收入為 471 萬美元，而分析師預期為 541 萬美元。Protagonist Therapeutics 的股本回報率為 6.86%，淨利潤率為 21.94%。研究分析師預測 Protagonist Therapeutics, Inc. 本年度將發佈 2.43 美元的每股收益。</p>
<h2>分析師評級上調和下調</h2>
<p>幾位分析師最近對該股票發表了看法。BTIG Research 在 10 月 28 日星期二的研究報告中重申了 &#34;買入&#34; 評級，並設定了 82.00 美元的目標價。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Protagonist Therapeutics 的 &#34;賣出（d+）&#34; 評級。HC Wainwright 在 10 月 8 日星期三重新發布了 &#34;買入&#34; 評級，並對 Protagonist Therapeutics 的股票設定了 80.00 美元的目標價。花旗集團在 12 月 8 日星期一將 Protagonist Therapeutics 的目標價從 98.00 美元上調至 115.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，摩根大通將 Protagonist Therapeutics 的目標價從 68.00 美元上調至 81.00 美元，並在 11 月 7 日星期五的報告中給予該公司 &#34;增持&#34; 評級。一位股票研究分析師對該股票給予了強烈買入評級，十一位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Protagonist Therapeutics 目前的平均評級為 &#34;適度買入&#34;，共識目標價為 85.08 美元。</p>
<p><strong>獲取我們關於 Protagonist Therapeutics 的最新股票報告</strong></p>
<h2>Protagonist Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Protagonist Therapeutics, Inc NASDAQ: PTGX 是一家臨牀階段的生物製藥公司，專注於開發新型口服給藥的肽類療法，針對免疫介導和其他嚴重疾病。該公司利用其專有的 Peptide 2.0 平台設計靶向 G 蛋白偶聯受體和細胞因子受體的肽，旨在將生物製劑的效力與口服給藥的便利性相結合。Protagonist 的方法旨在解決注射療法作為標準治療的領域中的未滿足醫療需求。</p>
<p>其主要項目之一是 PTG-100，一種口服 α4β7 整合素拮抗劑，旨在阻止白細胞遷移到潰瘍性結腸炎和克羅恩病的腸道中。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Protagonist Therapeutics</li>
<li>我不應該把這個發給你</li>
<li>揭示：美國剛剛解鎖了一個 500 萬億的資產</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>他們嘲笑 30 美元。他們不會再嘲笑 70 美元。</li>
<li>100 萬美元在退休後能維持多久？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Protagonist Therapeutics 嗎？</h2>
<p>在你考慮 Protagonist Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Protagonist Therapeutics 並不在名單上。</p>
<p>雖然 Protagonist Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Protagonist治療

<p>Assenagon Asset Management S.A. 在第三季度將其在 Protagonist Therapeutics, Inc. 的持股減少了 28.4%，目前持有 65,756 股，價值 437 萬美元。其他機構投資者也調整了他們的持股。Protagonist 的股票開盤價為 86.05 美元，市值為 53.8 億美元。分析師的評級不一，有些分析師上調了他們的目標價格</p>

<p>Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,756 shares of the company's stock after selling 26,119 shares during the period. Assenagon Asset Management S.A. owned 0.11% of Protagonist Therapeutics worth $4,368,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）股票中的持倉降低了 28.4%。該機構投資者在此期間出售了 26,119 股後，持有該公司 65,756 股股票。Assenagon Asset Management S.A. 在最近一個季度末持有 Protagonist Therapeutics 0.11% 的股份，價值 4,368,000 美元。</p>
</div><ul>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>強生的併購策略才是投資者真正關注的故事</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Guggenheim Capital LLC boosted its position in shares of Protagonist Therapeutics by 1.6% during the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company's stock worth $1,062,000 after acquiring an additional 303 shares in the last quarter. Bessemer Group Inc. lifted its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company's stock worth $28,000 after purchasing an additional 318 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Protagonist Therapeutics by 4.1% during the first quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock worth $405,000 after purchasing an additional 330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company's stock valued at $132,000 after purchasing an additional 340 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Protagonist Therapeutics by 0.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者最近也買賣了該公司的股票。Guggenheim Capital LLC 在第二季度將其在 Protagonist Therapeutics 的持倉增加了 1.6%。Guggenheim Capital LLC 目前持有該公司 19,208 股股票，價值 1,062,000 美元，此前在上個季度又增持了 303 股。Bessemer Group Inc. 在第二季度將其在 Protagonist Therapeutics 的股份提高了 171.0%。Bessemer Group Inc. 目前持有該公司 504 股股票，價值 28,000 美元，此前在上個季度又購買了 318 股。滙豐控股 PLC 在第一季度將其在 Protagonist Therapeutics 的股份提高了 4.1%。滙豐控股 PLC 目前持有該公司 8,458 股股票，價值 405,000 美元，此前在上個季度又增持了 330 股。未來資產全球投資有限公司在第二季度將其在 Protagonist Therapeutics 的持倉增加了 16.6%。未來資產全球投資有限公司目前持有該公司 2,394 股股票，價值 132,000 美元，此前在上個季度又購買了 340 股。最後，未來資產全球 ETF 持有有限公司在第一季度將其在 Protagonist Therapeutics 的股份增加了 0.9%。未來資產全球 ETF 持有有限公司目前持有該公司 37,403 股股票，價值 1,810,000 美元，此前在上個季度又增持了 348 股。目前，98.63% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Buying and Selling at Protagonist Therapeutics</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 的內部買賣</h2>
</div><p>In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director directly owned 5,130 shares in the company, valued at approximately $418,710.60. This trade represents a 70.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.90% of the company's stock.</p>
<div class="lb-trans"><p>在 Protagonist Therapeutics 的其他消息中，董事 William D. Waddill 於 10 月 10 日星期五出售了 12,000 股 Protagonist Therapeutics 股票。該股票以平均價格 81.62 美元出售，總價值為 979,440.00 美元。交易後，該董事直接持有該公司 5,130 股股票，價值約 418,710.60 美元。此交易代表其持倉減少了 70.05%。該出售在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。公司內部人士持有該公司 4.90% 的股票。</p>
</div><h2>Protagonist Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 股票表現</h2>
</div><ul>
<li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>這隻小型生物科技股票是否還有（更多）大幅上漲的空間？</li>
</ul>
</div><p>NASDAQ PTGX opened at $86.05 on Monday. The firm's fifty day moving average is $83.39 and its two-hundred day moving average is $66.53. Protagonist Therapeutics, Inc. has a one year low of $33.70 and a one year high of $96.54. The firm has a market cap of $5.38 billion, a PE ratio of 138.79 and a beta of 2.19.</p>
<div class="lb-trans"><p>NASDAQ PTGX 週一開盤價為 86.05 美元。該公司的 50 日移動平均線為 83.39 美元，200 日移動平均線為 66.53 美元。Protagonist Therapeutics, Inc. 的一年最低價為 33.70 美元，一年最高價為 96.54 美元。該公司的市值為 53.8 億美元，市盈率為 138.79，貝塔值為 2.19。</p>
</div><p>Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to analysts' expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protagonist Therapeutics（NASDAQ:PTGX - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告的每股收益（EPS）為（0.62）美元，低於分析師一致預期的（0.59）美元，差距為（0.03）美元。該公司本季度的收入為 471 萬美元，而分析師預期為 541 萬美元。Protagonist Therapeutics 的股本回報率為 6.86%，淨利潤率為 21.94%。研究分析師預測 Protagonist Therapeutics, Inc. 本年度將發佈 2.43 美元的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>Several analysts have recently weighed in on the stock. BTIG Research restated a &#34;buy&#34; rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, October 8th. Citigroup raised their price objective on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, JPMorgan Chase &amp; Co. boosted their target price on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $85.08.</p>
<div class="lb-trans"><p>幾位分析師最近對該股票發表了看法。BTIG Research 在 10 月 28 日星期二的研究報告中重申了 &#34;買入&#34; 評級，並設定了 82.00 美元的目標價。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Protagonist Therapeutics 的 &#34;賣出（d+）&#34; 評級。HC Wainwright 在 10 月 8 日星期三重新發布了 &#34;買入&#34; 評級，並對 Protagonist Therapeutics 的股票設定了 80.00 美元的目標價。花旗集團在 12 月 8 日星期一將 Protagonist Therapeutics 的目標價從 98.00 美元上調至 115.00 美元，並給予該股票 &#34;買入&#34; 評級。最後，摩根大通將 Protagonist Therapeutics 的目標價從 68.00 美元上調至 81.00 美元，並在 11 月 7 日星期五的報告中給予該公司 &#34;增持&#34; 評級。一位股票研究分析師對該股票給予了強烈買入評級，十一位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Protagonist Therapeutics 目前的平均評級為 &#34;適度買入&#34;，共識目標價為 85.08 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Protagonist Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Protagonist Therapeutics 的最新股票報告</strong></p>
</div><h2>Protagonist Therapeutics Profile</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.</p>
<div class="lb-trans"><p>Protagonist Therapeutics, Inc NASDAQ: PTGX 是一家臨牀階段的生物製藥公司，專注於開發新型口服給藥的肽類療法，針對免疫介導和其他嚴重疾病。該公司利用其專有的 Peptide 2.0 平台設計靶向 G 蛋白偶聯受體和細胞因子受體的肽，旨在將生物製劑的效力與口服給藥的便利性相結合。Protagonist 的方法旨在解決注射療法作為標準治療的領域中的未滿足醫療需求。</p>
</div><p>Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.</p>
<div class="lb-trans"><p>其主要項目之一是 PTG-100，一種口服 α4β7 整合素拮抗劑，旨在阻止白細胞遷移到潰瘍性結腸炎和克羅恩病的腸道中。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Protagonist Therapeutics</li>
<li>I Shouldn't Be Sending You This</li>
<li>REVEALED: America just unlocked a $500 trillion asset</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>They Laughed at $30. They Won’t Laugh at $70.</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Protagonist Therapeutics</li>
<li>我不應該把這個發給你</li>
<li>揭示：美國剛剛解鎖了一個 500 萬億的資產</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>他們嘲笑 30 美元。他們不會再嘲笑 70 美元。</li>
<li>100 萬美元在退休後能維持多久？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Protagonist Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Protagonist Therapeutics 嗎？</h2>
</div><p>Before you consider Protagonist Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Protagonist Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Protagonist Therapeutics 並不在名單上。</p>
</div><p>While Protagonist Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Protagonist Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Assenagon Asset Management S.A. 減少了其在 Protagonist 治療公司 $PTGX 的股票持有量